KLOW (80 mg Blend) Dosage Protocol

Dosing & Reconstitution Overview

KLOW is a multi-peptide research blend that combines four compounds in a single 80 mg vial: TB-500 (10 mg), BPC-157 (10 mg), KPV (10 mg) and GHK-Cu (50 mg). The figures below are compiled strictly for laboratory and educational reference — they describe how the blend is handled and measured in regeneration-focused research, not a recommendation for use in humans or animals.

For an 80 mg vial, adding 3.0 mL of bacteriostatic water yields a combined concentration of roughly 26.7 mg/mL. Because the components are present in fixed ratios, that single fill delivers approximately 3.33 mg/mL each of TB-500, BPC-157 and KPV, alongside about 16.7 mg/mL of GHK-Cu. At this concentration, every 0.075 mL drawn on a U-100 insulin syringe equals 7.5 units and supplies the lowest titration step, so the per-component microgram math stays consistent across the schedule.

Standard (Gradual) Titration Schedule

The gradual schedule eases into the blend over the first month, then settles into a higher working step before tapering to a maintenance level for extended runs. Each row lists the per-component amount delivered, since the blend moves as a single draw.

Reconstitution Steps

1. Allow the sealed lyophilized vial and the bacteriostatic water to reach room temperature, which limits condensation, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water with a sterile syringe and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl or roll gently until the material is fully dissolved. Do not shake, as foaming and agitation can shear the peptides.
4. Confirm the solution is clear before use, then label the vial with the combined concentration (~26.7 mg/mL) and the reconstitution date.
5. Refrigerate at 2–8 °C between uses, protected from light, and draw each subsequent volume with a fresh sterile syringe.

Working-Step Reference Schedule

The source presents a single gradual protocol rather than a separate aggressive arm, so the table below restates the same fill at its three active draw volumes for quick bench reference — the lowest break-in step, the standard step and the peak working step.

Supplies Needed

• KLOW vials (80 mg): ~3 vials for an 8-week run; ~4 vials for a 12-week run; ~5 vials for a 16-week run.
• Insulin syringes (U-100, 1 mL): ~56 for 8 weeks, ~84 for 12 weeks, ~112 for 16 weeks — one fresh syringe per daily draw.
• Bacteriostatic water (10 mL): one bottle covers an 8-week run; two bottles for 12–16 weeks.
• Alcohol swabs: roughly 110–170 for 8–12 weeks (2 × 100-count boxes); ~220 for a 16-week schedule (3 boxes).

Protocol Overview

• Research goal: model tissue repair, inflammation modulation and connective-tissue support through synergistic multi-peptide action.
• Schedule: once-daily subcutaneous administration in the published handling model.
• Cycle length: 8–12 weeks, with an optional extension to 16 weeks.
• Fill: 80 mg lyophilized (four components), reconstituted to ~26.7 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted, avoiding freeze–thaw.

Dosing Protocol Notes

• Begin at the 7.5-unit (0.075 mL) break-in step and hold it for the first two weeks.
• Step up to 15 units by Week 3 and to the 22.5-unit peak by Week 5 as tolerability is established.
• For extended protocols, drop back to the 15-unit maintenance step rather than holding the peak.
• Keep administration on a fixed daily cadence at a consistent time, and rotate sampling sites between draws.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light and moisture, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within roughly 14–28 days. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze–thaw cycles, and let vials reach room temperature before opening to limit condensation.

Important Handling Notes

• Use a new sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling sites (abdomen, thighs, upper arms) to reduce local irritation and keep the stopper intact.
• Inject slowly and pause a few seconds before withdrawing the needle to limit backflow.
• Document each draw — date, volume, site and remaining material — for reproducibility.

How the KLOW Blend Works

KLOW combines four research peptides whose mechanisms are complementary. TB-500 (a thymosin β4 fragment) is studied for promoting angiogenesis, cell migration and tissue repair through its regulation of actin, a core structural protein. BPC-157, a gastric pentadecapeptide fragment, is associated with tendon, ligament and muscle healing via enhanced angiogenesis and growth-factor modulation. KPV, the C-terminal tripeptide of α-MSH, carries anti-inflammatory activity, inhibiting NF-κB signalling and reducing pro-inflammatory cytokines. GHK-Cu, a copper-binding tripeptide, is studied for stimulating collagen and elastin synthesis, supporting wound healing and modulating genes tied to tissue remodelling. Combining all four is what distinguishes the blend from any single-peptide protocol in the comparative literature.

Reported Benefits & Side Effects

Benefits reported in research

• Accelerated tissue repair and wound healing across multiple complementary pathways.
• Reduced inflammation via NF-κB inhibition and cytokine modulation.
• Enhanced collagen synthesis and connective-tissue support.
• Promotion of angiogenesis and improved blood flow to recovering tissue, with potential musculoskeletal and joint support.

Side effects reported

• Mild injection-site reactions such as redness or irritation may occur.
• Occasional lightheadedness has been noted, attributed to vasodilatory effects.
• Human clinical data are limited; most safety observations derive from preclinical work.

Supporting Lifestyle Factors (Research Context)

• Protein-forward nutrition to provide substrate for tissue repair and recovery.
• Combined resistance training and mobility work to support musculoskeletal adaptation.
• Adequate sleep and stress management to support natural regenerative processes.
• Sufficient hydration as a standard supportive control.

Injection Technique (Reference Only)

• Clean the vial stopper and the site with alcohol swabs and let them dry completely.
• Pinch a skinfold and insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Inject slowly and steadily, then apply gentle pressure after withdrawal without massaging the site.
• Rotate sites systematically (abdomen, thighs, upper arms) and dispose of sharps in an approved container.

References

Related Protocols